Daniel J Holder
Overview
Explore the profile of Daniel J Holder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
674
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Papasavvas E, Azzoni L, Ross B, Fair M, Yuan Z, Gyampoh K, et al.
Clin Infect Dis
. 2021 Feb;
72(3):495-498.
PMID: 33527127
Accurate characterization of the human immunodeficiency virus (HIV) reservoir is imperative to develop an effective cure. HIV was measured in antiretroviral therapy-suppressed individuals using the intact proviral DNA assay (IPDA),...
2.
Holder D, Marino M
Curr Protoc Pharmacol
. 2017 Mar;
76:A.3G.1-A.3G.26.
PMID: 28306153
Lack of reproducibility has been highlighted as a significant problem in biomedical research. The present unit is devoted to describing ways to help ensure that research findings can be replicated...
3.
Li Y, Hafey M, Duong H, Evers R, Cheon K, Holder D, et al.
Toxicol Sci
. 2017 Jan;
157(1):30-40.
PMID: 28108666
Drug-induced liver injury (DILI) is a common toxicity observed in drug development and can lead to withdrawal of approved drugs from the market. To better understand the numerous mechanisms of...
4.
Burch P, Glaab W, Holder D, Phillips J, Sauer J, Walker E
Toxicol Sci
. 2016 Nov;
156(1):11-13.
PMID: 27815493
One of the goals of the Critical Path Institute's Predictive Safety Testing Consortium (PSTC) is to promote best practices for evaluating novel markers of drug induced injury. This includes the...
5.
Phillips J, Holder D, Ennulat D, Gautier J, Sauer J, Yang Y, et al.
Toxicol Sci
. 2016 Mar;
151(2):214-23.
PMID: 27026710
Traditional kidney biomarkers are insensitive indicators of acute kidney injury, with meaningful changes occurring late in the course of injury. The aim of this work was to demonstrate the diagnostic...
6.
Savage M, Holder D, Wu G, Kaplow J, Siuciak J, Potter W
J Alzheimers Dis
. 2015 Mar;
46(2):431-40.
PMID: 25790831
β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) plays an important role in the development of Alzheimer's disease (AD), freeing the amyloid-β (Aβ) N-terminus from the amyloid-β protein precursor (AβPP), the...
7.
Seeburger J, Holder D, Combrinck M, Joachim C, Laterza O, Tanen M, et al.
J Alzheimers Dis
. 2014 Nov;
44(2):525-39.
PMID: 25391385
Cerebrospinal fluid (CSF) amyloid-β (Aβ) and tau have been studied as markers of Alzheimer's disease (AD). Combined Aβ42 and t-tau distinguishes AD from healthy controls with a sensitivity and specificity...
8.
Zhao X, Lejnine S, Spond J, Zhang C, Ramaraj T, Holder D, et al.
J Alzheimers Dis
. 2014 Aug;
43(2):549-63.
PMID: 25114072
Biomarkers currently used in the aid for the diagnosis of Alzheimer's disease (AD) are cerebrospinal fluid (CSF) protein markers and brain neuroimaging markers. These biomarkers, however, either involve semi-invasive procedures...
9.
Dobrowolska J, Michener M, Wu G, Patterson B, Chott R, Ovod V, et al.
J Neurosci
. 2014 Jun;
34(24):8336-46.
PMID: 24920637
BACE, a β-secretase, is an attractive potential disease-modifying therapeutic strategy for Alzheimer's disease (AD) as it results directly in the decrease of amyloid precursor protein (APP) processing through the β-secretase...
10.
Zhang X, Santini F, Lacson R, Marine S, Wu Q, Benetti L, et al.
Bioinformatics
. 2011 Aug;
27(20):2775-81.
PMID: 21846737
Motivation: Off-target activity commonly exists in RNA interference (RNAi) screens and often generates false positives. Existing analytic methods for addressing the off-target effects are demonstrably inadequate in RNAi confirmatory screens....